In:
International Journal of Cancer, Wiley, Vol. 137, No. 10 ( 2015-11-15), p. 2470-2477
Abstract:
What's new? The spread of malignant cells in metastatic colorectal cancer is facilitated by urokinase plasminogen activator receptor (uPAR), a membrane‐anchored protein with multiple cleaved forms, some of which circulate in the blood. This study shows that one of those forms, uPAR(I‐III)+(II‐III), is a prognostic biomarker in metastatic colorectal cancer, being associated specifically with short overall survival. Furthermore, patients with KRAS wild‐type tumors and low levels of soluble uPAR(I‐III)+(II‐III) benefited more from FLOX (fluorouracil, folinate, and oxaliplatin) and cetuximab treatment regimens than patients with high suPAR levels. The findings suggest that suPAR influences therapeutic response, particularly to the EGFR inhibitor cetuximab.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8